Dr Reddy’s recalls Ranitidine tablets in the US

Recall was initiated by the company because of “microbial contamination of non-sterile products, said US FDA
Comment E-mail Print Share
First Published: Thu, Aug 22 2013. 05 19 PM IST
Shares of Dr. Reddy’s rose by 3.66% to `2,120 on BSE, while the exchange’s benchmark Sensex gained 2.27% to 18,312.94 points. Photo: Mint
Shares of Dr. Reddy’s rose by 3.66% to Rs.2,120 on BSE, while the exchange’s benchmark Sensex gained 2.27% to 18,312.94 points. Photo: Mint
Dr. Reddy’s Laboratories Ltd has voluntarily recalled three lots of its over-the-counter antacid drug Ranitidine Hydrochloride 150 mg in the US market.
An enforcement notification issued by US Food and Drug Administration (FDA) said the recall was initiated by the company because of “microbial contamination of non-sterile products”.
“A lot of raw material used in the manufacture of Ranitidine was positive for Pseudomonas sp,” the FDA report said. Pseudomonas sp is a type of bacteria.
Dr. Reddy’s said the financial impact of the recall is “negligible”.
Ranitidine is manufactured at the Shreveport facility of Dr. Reddy’s in Louisiana. Ranitidine was the first generic product launched by Dr. Reddy’s in the US market.
Shares of Dr. Reddy’s rose by 3.66% to Rs.2,120 on BSE, while the exchange’s benchmark Sensex gained 2.27% to 18,312.94 points.
Comment E-mail Print Share
First Published: Thu, Aug 22 2013. 05 19 PM IST
More Topics: Dr.Reddy’s | Ranitidine | US FDA |
blog comments powered by Disqus
  • Wed, Nov 19 2014. 04 58 PM
  • Wed, Nov 12 2014. 05 13 PM
Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved